Latest news with #Certis
CNA
12 hours ago
- CNA
Certis employee, 47, dies after collapsing during NDP rehearsal at Padang
SINGAPORE: A 47-year-old Certis employee has died after collapsing during a National Day Parade (NDP) rehearsal at the Padang on Saturday (Jun 21). The man was part of the OneChangi contingent for the Parade and Ceremony segment. He collapsed at 11.23am at the end of a component rehearsal, the Ministry of Defence (MINDEF) and Changi Airport Group (CAG) said in a joint media release. "He was immediately evacuated to the on-site medical post and arrived at 11.26am, where he was attended by the duty medical officer. Cardiopulmonary resuscitation was administered immediately," they added. The man remained unresponsive and was transferred to a standby Singapore Armed Forces ambulance at 11.42am. "Resuscitation efforts continued en route to hospital", said MINDEF and CAG. The man arrived at Singapore General Hospital at 11.57am and was pronounced dead at 12.19pm. The OneChangi contingent is made up of nine companies, including Certis and CAG. It is among the 18 civilian contingents participating in the NDP, which will be held on Aug 9 to mark Singapore's 60th birthday. "We are currently working closely with MINDEF and Changi Airport Group to further provide the officer's family with the necessary support and assistance," said Certis spokesperson Robin Goh.
Yahoo
20-05-2025
- Business
- Yahoo
Certis unboxes 'robocop' as it explores use of humanoid robots
SINGAPORE, May 20, 2025 /PRNewswire/ -- Singapore-based tech security powerhouse Certis has received its first humanoid robot, marking a new step in its push to explore how artificial intelligence (AI) and robotics could reshape frontline operations in an increasingly tech-driven services sector. The robot, developed by robotics firm Agibot, was delivered last week under a memorandum of understanding (MOU) signed between the two companies in February. Under the agreement, both parties will explore how humanoid robots might be used in security and integrated facilities management, although Certis said no deployment decisions have been made for now. Described as a research and evaluation initiative, the partnership will focus on understanding how humanoid robots could eventually complement human roles in complex operational settings, at commercial buildings, transport hubs or customer-facing environments, in the areas of security, operations and facilities management, as a start. "This collaboration represents a shift in how we think about technology integration," said Mr Leonard Oh, chief executive of Certis' technology services business. "We are exploring how humanoid robotics might complement our workforce and integrate with our existing operational ecosystems in meaningful ways — whether by enhancing service touchpoints, improving responsiveness, or unlocking new modes of human-technology interaction." The robot will be tested for integration with Certis' existing platforms, including its proprietary Mozart orchestration system, which enables coordination across security, facilities and customer service operations. The company emphasised that it is not conducting a live deployment at this stage, but instead is studying the robot's capabilities, interface compatibility, and potential fit within its wider operational ecosystem. This is the first time Certis is employing the use of a humanoid robot, though it has deployed other forms of robotics in recent years. These include autonomous mobile surveillance units used for patrolling high-security sites, and earlier-generation service robots that were trialled in commercial buildings for tasks such as thermal screening, temperature taking and concierge assistance during the COVID-19 pandemic. The new robot differs from previous deployments in its humanoid design and AI capabilities, which are aimed at enabling human interaction, navigation and service delivery in indoor environments. It features mobility functions and interactive elements, and is designed to operate alongside human staff, rather than replace them. Agibot's general manager of sales, Mr Xiong Jilin, said the partnership would allow the firm to explore real-world deployment scenarios, especially in service environments with high operational demands. "This partnership will allow us to test how humanoid robots can be applied thoughtfully and responsibly in real-world settings, and test the usability and acceptance of using such robots in security, facilities management and guest management settings," he said. The move comes as Singapore steadily increases its adoption of robotics and automation across sectors, particularly in response to labour shortages and a national push toward productivity gains. The country's National Robotics Programme has backed research and pilot projects across areas such as cleaning, logistics, healthcare and transport. Autonomous floor-scrubbing robots are now a common sight in shopping malls and airport terminals, while delivery bots have been trialled in residential estates and university campuses. "This partnership between Certis and Agibot speaks to Singapore's strength as a trusted global hub for robotics and embodied AI innovation and adoption," said Mr Tung Meng Fai, Executive Director, National Robotics Programme. "We are encouraged that Certis is taking the lead to explore new solutions and technologies to augment its workforce and uplift the security industry." In the private sector, hospitality chains, hospitals and public infrastructure operators have also adopted robotic assistants for concierge, navigation and logistics tasks. Despite the growing presence of robots in the public sphere, humanoid robots remain relatively uncommon in operational use, due to higher costs, technological complexity, and evolving questions around user interaction, safety and scalability. Certis acknowledged that humanoid robotics remained in its early stages, with part of a longer-term strategy to assess what role such technologies could play in augmenting its services for its customers. "While the capabilities of humanoid robots are promising, practical integration still requires careful consideration—across people, processes and platforms," Mr Oh said. "Ultimately, our goal is to shape technology that works alongside people, not in place of them." About Certis ( Backed by decades of experience in security, Certis is a leader today in smart integrated operations, leveraging technology to power transformations in security, manpower, facilities and property management solutions. Guided by our Operational Design First philosophy, our vast service offerings capitalise on our strong security heritage and deep operational expertise, enhanced with applied AI solutions for better decision making and outcomes. Central to our approach is our unique Business Process Re-engineering and Operations (BPRO®) framework, where we help customers manage change and enhance efficiencies through design thinking and a problem-solving approach. Incorporated in 2004, Certis is headquartered in Singapore, with an international presence extending to Australia and Qatar. We are a trusted partner dedicated to our clients' success, supported by our 26,000-strong global team, always striving to make our world safer, smarter, better. View original content to download multimedia: SOURCE Certis Sign in to access your portfolio
Yahoo
12-02-2025
- Business
- Yahoo
Certis Oncology Announces Issuance of U.S. Patent for Its Proprietary CertisAI Predictive Oncology Intelligence™ Platform
Invention Titled "Artificial Intelligence for Identifying One Or More Predictive Biomarkers" SAN DIEGO, February 12, 2025--(BUSINESS WIRE)--Certis Oncology Solutions, a precision oncology and translational science company, announced today that the United States Patent and Trademark Office (USPTO) has allowed a patent application directed to Certis's predictive artificial intelligence/machine learning (AI/ML) platform, CertisAI™. "The patent marks an important milestone for our company," said Peter Ellman, President and CEO of Certis. "It substantiates the uniqueness of our proprietary platform and the underlying methods for predicting drug response," he said. "By offering CertisAI as a service, we are democratizing access to powerful AI/ML tools, leveling the playing field for biopharmaceutical companies that may lack the internal resources required to build proprietary AI into their workflows." The company launched CertisAI in April 2024 as an extension of its preclinical biopharmaceutical services offering. The platform brings data-driven precision to a variety of early development decisions and provides a virtual environment in which to test and validate hypotheses related to drug efficacy, resistance and synergies. By correlating drug features and drug response with gene expression signatures, CertisAI can optimize preclinical model selection for drug efficacy studies and inform patient enrollment criteria for clinical trials—commonly cited causes of failed development programs. In silico analyses also can inform regulatory strategies, including label expansion and drug repurposing. The patent broadly protects a predictive AI/ML platform that integrates multiple data sets including drug features, gene expression biomarkers, and drug response, as well as the use of patient-derived xenograft (PDX) for model validation. The patent protection is expected to last until March 2043. About CertisAI™ CertisAI™ is a patented predictive artificial intelligence/machine learning (AI/ML) platform developed by Certis Oncology Solutions. It is the first and only commercially available, validated AI/ML platform that predicts therapeutic efficacy by identifying complex gene expression signatures that correlate with drug response. The platform is designed to assist pharmaceutical researchers to develop and clinicians to identify new treatment options for specific cancers based on a tumor's unique gene expression profile. About Certis Oncology Solutions Certis Oncology Solutions is a life science technology company committed to realizing the promise of precision oncology. The company's product is Oncology Intelligence® — highly predictive therapeutic response data derived from advanced models of cancer. We partner with physician-scientists and industry researchers to expand access to precision oncology and close the problematic translation gap between preclinical studies and clinical trials. Since its founding in 2016, Certis has offered personalized functional testing to help inform individual cancer treatment decisions, an approach advocated by cancer researchers and oncology clinicians worldwide. Using our patented artificial intelligence/machine learning platform and more clinically relevant, patient-derived tumor models, we bring certainty to drug development decisions and help secure clear and compelling evidence of drug efficacy. Certis operates a CLIA-certified, AAALAC- and OLAW-accredited laboratory in Sorrento Valley, the heart of San Diego's life sciences industry. For more information about Certis, visit View source version on Contacts MEDIA CONTACTCertis Oncology SolutionsKristein Kingkking@ 573-818-4528
